Total: $238.456M |
||||
Company (Symbol)# | Type Of | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
| | ||||
Ariad Pharmaceuticals | Private placement of common stock | 2.2S | $6.1 | Ariad raised $6.1M in a placement of 2.2M shares at $2.75 per share; Rodman & Renshaw Inc. served as placement agent for the offering (11/11) |
Cellegy Pharmaceuticals | Private placement of common stock | 2.2S | $5.5 | Company raised $5.5M in a private placement of its common stock to John Gregory, the managing partner at SJ Strategic Investments LLC (11/7) |
Discovery Labs | Private placement of common stock | 6.4S | $12.8 | Discovery Laboratories raised $12.8M in a private placement led by BioAsia Investments; other investors were Heartland Value Fund, Special Situations Funds, State Street Research Health Science Fund, PharmaBioDevelopment Inc., SDS Capital Partners, DMG LLC and others; the placement agent was Gerard Klauer Mattison & Co. Inc. (11/6) |
ISTA Pharmaceuticals | Private placement of common stock and warrants | N/A | $40 | ISTA completed a private placement of $40M of its common stock and warrants exercisable for an additional $6M of common stock to investors, including The Sprout Group, Sanderling Venture Partners, Investor Growth Capital Ltd., Gund Investment Corp., KBL Healthcare, MDS Capital and the Ontario Teachers' Pension Plan Board (11/20) |
Ligand Pharmaceuticals | Private placement of convertible subordinated notes | N/A | $135 | Ligand raised $135M with a private placement of its 6% convertible subordinated notes due Nov. 16, 2007; the notes are convertible into shares of Ligand common stock at $6.17 per share (11/21) |
Miravant | Convertible | N/A | - | Miravant signed a nonbinding letter of intent with a private party for a convertible line of credit up to $12M; the funds will be available in increments of up to $1M per month with associated warrants for shares of common stock (11/22) |
NeoTherapeutics | Private placement of common stock | N/A | $1.566 | NeoTherapeutics raised $1.566M in two separate private placements, one issuing 356,926 shares and raising $628,190 to be used to pay off debt to five vendors, and the other raising $938,000 by selling stock to five investors, who also received five-year warrants to purchase up to an aggregate of 107,870 shares of common stock at an exercise price of $3 per share (11/21) |
Ortec | Private placement of common stock | N/A | $8.7 | Ortec closed an $8.7M private placement with new and existing institutional investors (11/14) |
Palatin Technologies | Private placement of common stock | 9.37S | $11.5 | Palatin raised $11.5M with a private placement of 9.37M shares; for every five shares purchased, investors received a five-year warrant to purchase one common stock share at a 25% premium to the $1.23 per-share purchase price in the offering (11/20) |
Photogen Technologies | Private placement of common stock | N/A | $9 | Photogen sold $9M of common stock; investors were Mi3 LP, Oxford Biosciences and Tannebaum LLC (11/15) |
TM Bioscience Corp. (Canada; CDNX:TMC) | Debt financing | N/A | - | Tm Bioscience closed a debt financing with Canadian Medical Discoveries Fund Inc. for C$4.67M (US$2.96M); the loan has a term of 39 months (11/13) |
Transition Therapeutics | Private placement of common stock | 5.7S | C$2 | Transition raised US$1.29M in a private placement (11/27) |
ViroLogic | Private placement of preferred stock | N/A | $7 | ViroLogic raised $7M through the sale of newly issued shares of 8% convertible preferred stock to a group of unnamed investors; the purchasers also will receive warrants to purchase a total of 4.4M shares of common stock at a price based on a five-day trading average (11/15) |
| | ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
N/A = Not available, applicable or reported. | ||||
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board | ||||
